Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD – Swift Hydrocortisone Intervention after Trauma Exposure
2025-523350-13-02Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing Hydrocortisone with Placebo (2 arms). Primary endpoint: PTSD symptom severity at 3 months. Planned start Mar 2026; status: authorised.
02
Drugs
hydrocortisone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2025-523350-13-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523350-13-02.